February 22, 2024 - by Catie Corcoran

NeuroSense Reports Additional Positive Data from ALS Trial

22 February 2024

New York, February 22, 2024 - PRISM MarketView -Neurodegenerative disease company, NeuroSense Therapeutics (Nasdaq: NRSN) has reported additional positive data from its six-month double-blind Phase 2b PARADIGM trial of PrimeC for the treatment of amyotrophic lateral sclerosis (ALS).

NeuroSense Therapeutics Ltd. - Prism MarketView

NeuroSense Therapeutics is a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurode

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial - Prism MarketView

PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALSStandard ALS Measure ALSFRS-R already demonstrated a statistically significant...

PrimeC displayed a clinically meaningful effect on various aspects of patients’ quality of life, including mental and physical health, and achieved an improvement in complication-free survival compared to placebo, reducing the risk of ALS disease complications or death by up to 53%.

“The positive impact of PrimeC on quality of life and complication-free survival, together with its demonstrated ability to meaningfully slow down disease progression, is of great value, as we see that we have the potential to profoundly affect patients’ lives across the board. We are in great anticipation to soon report on the status of our collaboration on neurofilaments and how this may contribute to expediting the development of PrimeC.”

Alon Ben-Noon, NeuroSense’s CEO

Highlights

PARADIGM is a prospective, multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial of PrimeC in 68 participants with ALS.

96% of the trial participants who completed the 6-month double-blind portion of the trial chose to receive treatment with PrimeC through a 12-month open label extension.

PrimeC has been granted Orphan Drug Designation by FDA and the European Medicines Agency.

ALS is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

PRISM MarketView does not provide investment advice.

Media Contact
Company Name: Prism MarketView
Email: info@prismmarketview.com
Phone: 646-863-6341
Website: https://prismmarketview.com

To see this content properly accept cookies.

PRISM MarketView Social Media

To see this content properly accept cookies.